Purpose: Costly surveillance and treatment of bladder cancer can lead to financial toxicity, a treatment related financial burden. Our objective was to define the prevalence of financial toxicity among patients with bladder cancer and identify delays in care and its effect on health related quality of life. Materials and Methods: We identified patients with bladder cancer in the University of North Carolina Health Registry/Cancer Survivorship Cohort. Financial toxicity was defined as agreement with having "to pay more for medical care than you can afford." Health related quality of life was measured using general and cancer specific validated questionnaires. Statistical analyses were performed using the Fisher exact test and the Student t-test. Results: A total of 138 patients with bladder cancer were evaluated. Median age was 66.9 years, 75% of the patients were male and 89% were white. Of the participants 33 (24%) endorsed financial toxicity. Participants who were younger (p ¼ 0.02), black (p ¼ 0.01), reported less than a college degree (p ¼ 0.01) and had noninvasive disease (p ¼ 0.04) were more likely to report financial toxicity. On multivariable analysis only age was a significant predictor of financial toxicity. Patients who endorsed financial toxicity were more likely to report delaying care (39% vs 23%, p ¼ 0.07) due to the inability to take time off work or afford general expenses. On general health related quality of life questionnaires patients with financial toxicity reported worse physical and mental health (p ¼ 0.03 and <0.01, respectively), and lower cancer specific health related quality of life (p ¼ 0.01), physical well-being (p ¼ 0.01) and functional well-being (p ¼ 0.05).
Conclusions: Financial toxicity is a major concern among patients with bladder cancer. Younger patients were more likely to experience financial toxicity. Those who endorsed financial toxicity experienced delays in care and poorer health related quality of life, suggesting that treatment costs should have an important role in medical decision making.
Key Words: urinary bladder neoplasms, health care costs, patient outcome assessment, quality of life, surveys and questionnaires THE United States health care system prioritizes cutting edge technology and innovative pharmaceuticals, of which the costs have been progressively redirected to individual patients. The maintenance of our high quality of care and our use of expensive treatments must be balanced with patient QOL, which can be negatively impacted by financial stress. Interest in this problem has been growing since 2013, when the phrase FT was coined. FT, defined as treatment related financial distress, has been particularly relevant in the field of oncology, which often requires expensive treatments and long-term surveillance. 1 FT is a particular concern for patients with bladder cancer because of its high prevalence 2 and significant cost. Bladder cancer is the most expensive cancer from diagnosis to death 3, 4 due to longterm survival and ongoing surveillance. 5 Surveillance includes imaging and cystoscopy at frequent intervals for years, contributing up to 60% of the cost of bladder cancer care. 5 In addition to the direct costs of care, indirect costs of cancer treatment such as time away from work 6 also contribute to the burden of treatment. The negative impact of FT has garnered national attention from features on CBS 60 Minutes 7 to articles in The Washington Post 8 and The Wall Street JournalÒ. 9 Patients with cancer are 2.65 times more likely to declare bankruptcy than those without cancer. 10 Beyond obvious monetary consequences FT can also have negative long-term effects on cancer outcomes. FT requiring bankruptcy was recently linked to early mortality in patients with cancer.
11 Patients who report FT also show medication nonadherence, skip doctor appointments and refuse necessary procedures to offset costs. 1 While the prevalence and impact of FT have been studied in many common cancers such as breast 12 and lung 13 cancers, the effects of FT on patients with bladder cancer remain unknown. The objective of our study was to 1) assess the prevalence of FT and associated patient level factors among patients with bladder cancer, 2) evaluate patient reported delays in care and the reasons for those delays, and 3) examine the relationship between FT and HRQOL. To our knowledge this is the first study to evaluate the prevalence and impact of FT in the bladder cancer population.
MATERIALS AND METHODS
We performed a cross-sectional study of 138 patients with bladder cancer identified in the UNC HR/CSC, an incident prevalent cohort of oncology patients recruited from August 2010 to August 2016. To be eligible for HR/CSC patients were required to be an English or Spanish speaking adult 18 years old or older, and have a North Carolina mailing address and an upcoming oncology appointment in the UNC Health Care System.
After screening for eligibility patients were recruited in person during a visit to UNC and informed consent was obtained at that time. A baseline questionnaire was administered, typically within 2 weeks of enrollment, by a computer assisted telephone interview that lasted approximately 1 hour. The baseline questionnaire was extensive, including information on demographics, previous health care access and services, diagnosis and treatment, FT and HRQOL. Among this cohort we identified patients with pathologically confirmed, primary cancer of the bladder.
Patients enrolled in HR/CSC were clinically annotated with diagnostic pathology and first course of treatment data via the UNC Hospital Tumor Registry. This was linked to more extensive clinical data in CDW-H (Carolina Data Warehouse for Health), where information is gathered from the electronic medical record. Additional patient details were manually abstracted from the electronic medical record, including important treatment information (eg chemotherapy cycles and intravesical treatments).
We defined FT as the patient selection of agree or strongly agree with the statement, "You have to pay more for medical care than you can afford," on PSQ-18 (Patient Satisfaction Questionnaire-18), which was also used in other FT analyses. 14 We examined the association between baseline FT and HRQOL using general and cancer specific scales with FACT, 15 including a bladder cancer specific FACT questionnaire and the PROMIS 16 questionnaire. Descriptive statistics were used to summarize all study variables. Patients were categorized into 2 groups based on FT endorsement. The Fisher exact test and the Student t-test were used to evaluate differences in demographic, diagnostic and treatment characteristics between the FT groups. All analyses were completed with SASÒ, version 9.3. This study was reviewed and approved by the UNC institutional review board.
RESULTS
Among 144 patients with bladder cancer enrolled in HR/CSC 138 (96%) completed the baseline questionnaire and were included in analysis. Median age was 66.9 years, 75% of the patients were male, 89% were white and 66% had less than a college degree (supplementary 
DISCUSSION
To our knowledge we report the first study of the prevalence and impact of FT among patients with bladder cancer. We observed that almost a quarter of patients with bladder cancer in our institutional bladder cancer cohort endorsed treatment related financial distress. Patients who reported FT were more likely to be younger, black, have less than a college degree and have a noninvasive cancer diagnosis. However, stage was not associated with FT on multivariable analysis. Moreover, delayed care and poorer HRQOL, general and cancer specific, were associated with patients who endorsed FT. Financial toxicity in oncology patients has been studied in a number of settings since 2010, when attention shifted toward the impact of increasing costs on patient reported outcomes. Until 2014 studies of FT used 3 different measurements, including subjective, objective and monetary. This inconsistency likely resulted in the wide variability in FT prevalence found among studies. A recent review showed a FT prevalence range of 16% to 73%. 17 In 2014 to address this variation the validated patient reported outcome measure COST was developed. 18 Although our study was initiated prior to implementation of the COST questionnaire, the 24% prevalence observed in the current study was within the prevalence range of studies in which similar FT measurements were used. 14,19e21 Working age patients have consistently reported a higher rate of FT. 10, 19, 20, 22, 23 This finding was supported in the current study based on age but not corroborated based on self-reported work status. Two main factors likely contribute to this finding, including the loss of work related income in working age patients 23 and the lack of universal access to health care prior to age 65 years, when United States residents are first eligible for Medicare benefits. Although insurance was not a statistically significant predictor of FT, there was a clear association between insurance level and FT. Those with private and Medicare insurance had the lowest FT rate compared to those with Medicaid and self-pay insurance. Additionally, we found that race and education were associated with FT, as previously reported. 14, 19, 24 However, time since diagnosis, distance traveled and previous treatment were not associated with FT in our study.
Although a history of cancer treatment was not associated with FT, stage appeared to be predictive on bivariable analysis with more patients who had noninvasive than invasive bladder cancer reporting FT. However, stage was not an independent predictor of FT on multivariable analysis. Only 1 other study has assessed the relationship between FT and cancer stage. 25 In that general cancer population more advanced cancer was associated with FT, contrary to our findings.
Those conflicting findings are likely a result of multiple factors. 1) Our study included an incident/ prevalent cohort while other studies may represent
Could not get through on phone
Could not get appointment Regardless of the association between stage and FT financial distress clearly impacts quality of life, health behaviors and outcomes. Prior research demonstrated a negative association between FT and HRQOL in patients with cancer. 21, 22, 24, 26 Our study supports this inverse relationship since patients with bladder cancer who endorsed FT reported poorer HRQOL on general and cancer specific questionnaires, and in most QOL subcategories. The HRQOL differences between FT and no FT were significant. Patients with FT had a lower average FACT-GP total score (e10), a lower average PROMIS global physical health score (e4) and a lower average PROMIS global mental health score (e5). The minimally important difference ranges from 3 to 7 for FACT-GP 15 and 5 (half the SD of 10) for PROMIS, 16 suggesting that these HRQOL differences are meaningful.
A 2010 study of patients with cancer using NHIS (National Health Interview Survey) data showed that patients who endorsed FT were also more likely to delay or forgo care and reduce prescription medications, dental care, eyeglasses and mental health care. 19 Our findings support these results in that patients with bladder cancer who endorsed FT were also more likely to delay care, although this did not reach statistical significance (p ¼ 0.07), possibly due to sample size. To determine possible interventions for this problem we evaluated reasons for delaying care. We examined hospital/clinic level factors such as the ability to make an appointment and patient level factors such as a lack of transportation. Two of the 14 potential reasons for care delays were associated with FT, including the inability to afford general expenses and the inability to miss work. These findings reflect that the most significant factors contributing to FT are likely high out-of-pocket treatment related costs and the loss of income related to missed work or decreased employment in working age patients. 27 Negative health behaviors such as delayed care can have worrisome consequences, including poor outcomes. Our study supports prior research that draws an association between FT and negative oncologic outcomes. 1, 10, 11, 21, 22, 24, 26 For a holistic approach to cancer treatment urologists have the responsibility to communicate costs to patients and include them in shared decision making. The importance of cost discussions was recently incorporated into the guidelines of multiple organizations, including ASCOÒ (American Society of Clinical Oncology).
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Unfortunately most clinicians do not discuss treatment costs with their patients despite the patient desire to discuss the topic. 29 Although many barriers exist (ie time, embarrassment and cost education), honest discussions regarding treatment expenses is a tangible step that can improve patient satisfaction, decrease out-of-pocket costs 29 and, thus, possibly mitigate some adverse effects of FT.
Ideally patient-physician interactions should be organized into 3 parts, including 1) discussion regarding treatment options, 2) financial counseling and 3) shared decision making.
Another mechanism to address FT related to bladder cancer involves a scrutiny of our surveillance practices. Among patients with noninvasive bladder cancer a large portion of the costs of care is related to extensive followup surveillance with expensive cystoscopy procedures and imaging. 5 Computerized tomography urography costs an average of $356 (range $270 to $467) while cystoscopy costs an average of $208 (range $166 to $258). 30 Costs may be surpassed by charges, which are often opaque, leading to a rapid accumulation of expenses, given stringent surveillance strategies.
In 2016 the AUA (American Urological Association) revised their guidelines to create a risk based strategy that relaxes surveillance among patients with low risk disease. However, guidelines for followup care continue to be largely based on expert opinion and lacking strong evidence. The creation of thoughtful, efficient followup algorithms offers a potential opportunity to improve patient care by decreasing the direct out-of-pocket costs and inconvenience (eg missed work) related to multiple yearly visits. Although there are benefits to close surveillance of bladder cancer, future studies must evaluate the optimal timing and benefits of followup surveillance to reduce the competing risk of FT.
Our study is not without limitations. The crosssectional design did not allow us to assess FT with time or assess for causal relationships. Longitudinal assessment would likely reveal important details about how FT impacts patients with this disease, particularly for bladder cancer, which has many parallels to chronic disease. Our study was also limited by the lack of a validated assessment tool such as COST, which was developed after the initiation of our study as previously mentioned. 18 Furthermore, this study was performed at a single institution and therefore, a larger multi-institutional study would be needed to establish the generalizability of results. Finally, we lacked comprehensive diagnostic and treatment data, which we attempted to address through retrospective chart review. However, not all patients were followed exclusively at our institution.
Despite these limitations our study has several strengths. As the first evaluation of FT among patients with bladder cancer to our knowledge our findings represent an opportunity to evaluate mechanisms to streamline costs and incorporate the effects of financial distress in shared decision making. Our detailed abstraction allowed for individual confirmation of the diagnosis and treatment of each patient. Our sample of patients with bladder cancer was also consistent with national trends of patients with bladder cancer except for the higher proportion of white patients. Our results must be externally validated in a larger, more nationally representative patient population.
CONCLUSIONS
We found that FT was a major concern of bladder cancer survivors and was associated with delays in care and poorer HRQOL. The etiology of FT is likely related to missed work opportunities and high outof-pocket health care costs. Cost communication should be a topic included in treatment discussions to improve shared decision making conversations. Furthermore, optimizing surveillance intervals could reduce extraneous out-of-pocket costs for patients, decrease the financial burden and improve patient outcomes. 
EDITORIAL COMMENT
Financial toxicity is an increasingly recognized side effect of cancer care. Like other side effects it is associated with acute, long-term and late effects that can adversely impact quality and even quantity of life. Delays in care, time off work, unpaid bills, and bankruptcy coupled with worse physical and mental health are serious adverse effects associated with financial toxicity. While it is often unrecognized by providers due to their focus on the disease, patients may face mounting financial toxicity as the duration and the intensity of cancer care increase. To our knowledge this study is the first to highlight real world financial toxicity in a bladder cancer population, showing that 1 of 4 patients agreed that medical care was more than they could afford. In addition, the investigators found that younger patients were more likely to experience financial toxicity, likely due to time away from work and lack of universal health care coverage (ie Medicare). They also report financial toxicity differences according to race and education, indicating the potential for worsening disparities in cancer care without proper attention. Through a rich discussion of financial toxicity among cancer survivors and a demonstration of its adverse biopsychosocial impacts among patients with bladder cancer in their cohort the authors motivate urologists to assess financial toxicity and implement strategies to minimize its impact in the care and lives of patients with bladder cancer.
How urologists might improve the current state to minimize the impact of financial toxicity among their patients warrants consideration. In light of evidence supporting the benefits of less intense surveillance of early stage disease 1 and the current risk based surveillance approaches mentioned in the article urologists could be proactive about adopting less intense and, therefore, less costly surveillance. In addition, investigators are exploring opportunities to decrease overtreatment in low risk, noninvasive bladder cancer through a prospective multi-institutional randomized trial evaluating observation vs immediate surgery. 2 If the ensuing evidence supports less intense treatment approaches, this would also facilitate risk based opportunities to decrease financial toxicity.
Lastly, the authors discuss the recently validated, 11-item COST patient reported outcome measure 3 as a means to assess financial toxicity and facilitate shared decision making for bladder cancer. While this was validated in patients with advanced cancer, the questions, including "I feel financially stressed" and "I worry about the financial problems I will have in the future as a result of my illness or treatment," serve as screening tools to start a meaningful discussion about the value of routine treatment of patients with bladder cancer at all stages of disease with respect to clinical benefit and toxicities, financial and otherwise. Increased attention to this once unrecognized adverse effect may prompt providers and patients at risk to leverage resources provided by hospitals, cancer centers and other organizations such as BCANÒ (Bladder Cancer Advocacy Network) and ACSÒ (American Cancer Society). And most importantly, acknowledging the life altering implications of financial toxicity may not only force us to reevaluate our current practices but also empower patients to make more informed decisions as they evaluate their resources and preferences.
REPLY BY AUTHORS
We agree that financial toxicity will be an unavoidable issue as health care costs increase, insurance coverage wavers and expensive new technologies enter the health care market. As urologists we cannot turn away from the problem. Health care providers are vital to minimize the impact of financial toxicity on patients. As mentioned, many opportunities already exist to decrease the financial impact in urology with regard to surveillance strategies and treatment selection. In our study we hoped to highlight the prevalence of financial toxicity among 1 patient population and, therefore, encourage further research in this important area. Embedding the COST patient reported outcome measure (reference 3 in comment) into ongoing and future studies may offer insight into the negative impact of treatment related financial burden in multiple urological populations.
Financial toxicity is a symptom that can be addressed but the first step requires a concerted effort among urologists to discuss the financial impact of diagnostic and treatment decisions.
